Science commentary stresses need for collaboration at local level in HIV-prevention studiesOctober 03, 2005Clinical trials of drugs intended to prevent HIV infection in high-risk populations must be developed and carried out in close collaboration with the local communities and national governments of the countries in which they are conducted, according to 18 international leaders in HIV prevention writing in the current (Sept. 30, 2005) issue of Science. Oral, daily use of the antiretroviral drug tenofovir is considered a key potential strategy for preventing infection of HIV. Clinical trials of the drug are in progress or proposed in numerous countries, including the U.S. The co-authors advocate early involvement of community leaders and local investigators in the development of HIV-prophylaxis clinical trials, clear communication of research information, and the involvement of the local leaders and investigators in the development of local prevention and treatment infrastructures. All too often, they note, studies in the last several years were marked by misinformation and miscommunication between these key constituencies. The commentary outlines key issues involved, pointing out that, in those cases, questions about how the research should be carried out proved to be more controversial than the idea of the clinical trial itself. "These recommended measures will help to build the type of local community trust that is the basis of successful research to find ways to stop the spread of HIV/AIDS," says lead author Robert Grant, MD, MPH, an associate investigator at the Gladstone Institute of Virology and Immunology and associate professor of medicine at the University of California, San Francisco (UCSF). "HIV pre-exposure chemoprophylaxis research is built on partnerships between sponsors, investigators, communities and governments." Gladstone Institutes |
|||||||||||||||||||||
| Related HIV-prevention Current Events and HIV-prevention News Articles An HIV-blocking gel for women University of Utah scientists developed a new kind of "molecular condom" to protect women from AIDS in Africa and other impoverished areas. Before sex, women would insert a vaginal gel that turns semisolid in the presence of semen, trapping AIDS virus particles in a microscopic mesh so they can't infect vaginal cells. Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS) (http://www.jaids.com/). Neutral HIV presentations more likely to be considered inviting, study finds A recent study by University of Illinois professor of psychology Dolores Albarracín and her colleagues at the University of Florida and the Alachua County Health Department in Florida found a method to increase enrollment among high-risk individuals in HIV prevention programs. PrEP strategy could dramatically slow the spread of HIV Giving a daily antiretroviral pill to people to prevent HIV could profoundly slow the spread of the infection in sub-Saharan Africa, where it is a full-blown epidemic, University of Pittsburgh School of Medicine researchers report. Study demonstrates successful HIV-prevention program for Latino youth A culturally tailored HIV-prevention program can help reduce risky sexual behaviors among Latino adolescents, even a year after students attended the training, according to a study led by University of Michigan and University of Pennsylvania researchers. More HIV-prevention Current Events and HIV-prevention News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||